World AMR Awareness Week 2023

Preventing antimicrobial resistance together

Narishaben Solanki receiving DOT program medication from Mikesh Vanuzu at the Hirabaug Health Centre, in Surat, India. 14.12.2017 © FIND/Ben Phillips

Testing to combat antimicrobial resistance in low-resource settings gets US$10 million boost from extended FIND–GAMRIF partnership

During World Awareness Week 2023 a new 4-year funding to FIND from the UK Department of Health and Social Care, through the Global AMR Innovation Fund (GAMRIF) was annouced.

Coffee chats: recent advances in AMR

Join Cassandra Kelly-Cirino, our VP Health Programmes, as she caught up with Fernando Pascual Martinez, R&D Access Development Lead at GARDP, to chat about recent advances in AMR including the Phase 3 zoliflodacin study, and our work together to support its use and strengthen management of sexually transmitted diseases.

AMRelay 2023 logo

Event to connect and honour global stakeholders in AMR

FIND is participating in this 24-hour, online event to connect and honour global stakeholders in AMR, which will take place on the last day of the WAAW 2023. The event will start at Coordinated Universal Time (UTC) 00:00 and end at UTC 24:00, following global timezones.

AMRelay is an initiative of AMR Insights and is realized in partnership with the Antimicrobial Resistance Fighter Coalition.

Rising threats: confronting AMR and STIs in 2023

Rising threats: confronting AMR and STIs in 2023

Thursday, 23 November 2023, 13:00–14:30 CET


Cassandra Kelly-Cirino, VP Health Programmes at FIND, will join this webinar organized by the departments of AMR and HIV/STIs at WHO to launch and discuss two WHO technical products that are under the Enhanced Gonococcal AMR Surveillance Programme (EGASP) umbrella.

WHO Global Research Agenda for AMR

(PDF, 1.00 MB, 12 pages)

This document, published earlier this year, will catalyze innovation and implementation research, spanning the epidemiology, burden and drivers of AMR, as well as context-specific and cost-effective strategies to prevent infections and emergence of resistance. The discovery of new diagnostic tests is identified as a priority.

TB also causes antimicrobial resistance related deaths

Global TB Report 2023

Rapid diagnostic tests and digital tools tailored for AMR must be available when and where people first access health services (i.e. in primary care and community settings) – particularly for management of diseases that rely heavily on antibiotics, like tuberculosis (TB).

Drug resistance needs more than medical attention

Reliable data are indispensable to the creation of policies and health interventions designed to combat AMR. With the global burden of AMR continuing to grow each year, we must stay one step ahead of the problem if we are to prevent it from spiraling out of control.

Read the opinion by Joseph Njunge and Veronicah Chuchu published in People Daily (Kenya) 

Find out more about our work in AMR

We are working to improve access to AMR testing and surveillance so that antibiotic drugs will continue to work for as long as possible and lives can be saved.

Any questions ?

Do not hesitate to contact us if you want to know more about our work on AMR.